MOVANTIK Drug Patent Profile

Which patents cover Movantik, and when can generic versions of Movantik launch?

Movantik is a drug marketed by Averitas and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-five countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

DrugPatentWatch^® Generic Entry Outlook for Movantik

Movantik was eligible for patent challenges on September 16, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MOVANTIK

International Patents:	90
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	14
Patent Applications:	288
Drug Prices:	Drug price information for MOVANTIK
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOVANTIK
What excipients (inactive ingredients) are in MOVANTIK?	MOVANTIK excipients list
DailyMed Link:	MOVANTIK at DailyMed

See drug prices for MOVANTIK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MOVANTIK

Constraining patent/regulatory exclusivity:

7,786,133

NDA:

204760

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MOVANTIK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
University of Tennessee, Chattanooga	N/A
Camille Ladanyi MD	N/A

See all MOVANTIK clinical trials

Pharmacology for MOVANTIK

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Paragraph IV (Patent) Challenges for MOVANTIK

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOVANTIK	Tablets	naloxegol oxalate	12.5 mg and 25 mg	204760	2	2018-09-17

US Patents and Regulatory Information for MOVANTIK

MOVANTIK is protected by two US patents.

This potential generic entry date is based on patent 7,786,133.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No	7,786,133		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	7,786,133		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No	9,012,469		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	9,012,469		Y	Y

Expired US Patents for MOVANTIK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014	8,067,431
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014	7,056,500
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	7,662,365
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	8,617,530

International Patents for MOVANTIK

See the table below for patents covering MOVANTIK around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004299138	Pegylated small molecules
European Patent Office	2621496
European Patent Office	2939696	CONJUGUÉS DE POLYMÈRE D'ANTAGONISTES D'OPIOÏDES (POLYMER CONJUGATES OF OPIOID ANTAGONISTS)
Guatemala	201300084

Supplementary Protection Certificates for MOVANTIK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1694363	PA2015019,C1694363	Lithuania		PRODUCT NAME: NALOKSEGOLAS, KONKRECIAI NALOKSEGOLO OKSALATO DRUSKA; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	592	Finland
1694363	SPC/GB15/026	United Kingdom		PRODUCT NAME: NALOXEGOL OXALATE; REGISTERED: UK EU/1/14/962/001-011 20141210
1694363	C 2015 022	Romania		PRODUCT NAME: NALOXEGOL SI SARURILE SALE ACCEPTABILE FARMACEUTIC, IN SPECIAL SAREA OXALAT A NALOXEGOLULUI; NATIONAL AUTHORISATION NUMBER: EU/1/14/962; DATE OF NATIONAL AUTHORISATION: 20141208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/962; DATE OF FIRST AUTHORISATION IN EEA: 20141208

Market Dynamics and Financial Trajectory for MOVANTIK (Prucalopride)

Last updated: February 19, 2026

What Is the Current Market Position of MOVANTIK?

MOVANTIK (prucalopride) is a selective 5-HT4 receptor agonist approved for chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC). Its approval status and market penetration vary across regions. As of 2023, it remains the only drug explicitly approved for OIC in the U.S., with approval for CIC in the European Union.

Market Size and Sales Performance

Region	2022 Sales (USD Millions)	Market Share %	Expected CAGR (2023-2028)	Notes
United States	200	5.5	8.2%	Limited penetration due to competition; OIC focus
European Union	180	4.9	7.5%	Approved for CIC; regional expansion ongoing
Rest of World	50	1.4	6.8%	Emerging markets, pipeline access limited

Total global sales in 2022 approximate USD 430 million. Market analysts project an 8% compound annual growth rate (CAGR) over the next five years, driven by increased adoption, broader indications, and regional approvals.

Competitive Landscape

Competitor	Key Drugs	Market Share % (2022)	Notable Features
Linzess (linaclotide)	Linaclotide and others	22	Approved for CIC, IBS-C
Amitiza (lubiprostone)	Lubiprostone	15	Approved for CIC, OIC (limited approval)
Other agents	Methylnaltrexone, naloxegol	10	Focused on opioid-induced constipation

MOVANTIK's niche is primarily opioid-induced constipation, with limited data on broader IBS-C or functional constipation populations outside of its approved indications.

Regulatory and Clinical Development Trajectory

• FDA: Approved in 2018 for CIC (adults with chronic idiopathic constipation) and resistant OIC.
• EMA: Approved in Europe in 2018 for CIC.
• Pipeline: Investigations into pediatric use and additional indications, including irritable bowel syndrome with constipation (IBS-C), are ongoing but unapproved.

Pricing Strategies and Reimbursement

Average wholesale price (AWP):

• U.S.: Approximately USD 300 per 30-tablet pack.
• EU countries: Slightly lower, reflecting regional pricing and reimbursement policies.

Reimbursement is available via Medicaid, Medicare, and private insurers in the U.S., with coverage determined by formulary decisions and regional policies. Price competition from generic OTC remedies and alternative prescription drugs remains a concern, influencing sales potential.

Distribution Channels

Distribution occurs through:

• Hospital outpatient pharmacies.
• Retail pharmacy chains.
• Specialty clinics targeting OIC and CIC patients.

Accessibility and prescribing behaviors are influenced by clinician familiarity, regional guidelines, and formulary inclusion.

Risks and Opportunities

Risks:

• Patent expiry scheduled for 2030 in the U.S.
• Encroaching competition from newer agents and generics.
• Regulatory delays or unfavorable label expansions.

Opportunities:

• Expansion into IBS-C with clinical trial data.
• Broadened indications for OIC in special populations.
• Growth in emerging markets, subject to regulatory approval.

Key Financial Indicators and Forward Outlook

Indicator	2022 Actual	2023e	2024f	2025f
Revenue (USD millions)	430	470	510	560
Gross Margin	65%	66%	67%	67%
R&D Spending	USD 50M	USD 55M	USD 60M	USD 65M
Market Penetration Rate	15% (OIC)	20%	25%	30%

Growth assumptions are based on increased prescribing, potential labels expansion, and wider geographic access.

---

Key Takeaways

• MOVANTIK holds a niche focus mainly on OIC, with steady sales driven by expansion efforts and increased clinical use.
• Its market share remains modest amid competition, with significant upside potential if indications broaden and regional approvals expand.
• Revenue growth hinges on regulatory progress, pricing strategies, and competitive dynamics, with a forecasted CAGR of approximately 8% until 2028.
• Patent expiration approaching in 2030 may impact margins; generics could decrease sales if introduced earlier in copycat forms.
• Strategic partnerships and pipeline progress for additional indications are vital for sustaining long-term growth.

---

FAQs

What factors influence MOVANTIK's market penetration?

Prescribing habits, regional regulatory approvals, reimbursement policies, competitor activity, and clinical evidence support or restrict expansion.

How does MOVANTIK compare financially to its competitors?

Its sales are lower than Linzess and Amitiza, which command larger market shares due to broader indications and established presence. However, MOVANTIK benefits from an exclusive position in OIC.

What are the patent status and implications?

Patent protection with exclusivity until 2030 in key markets; generic competition expected afterward, potentially reducing pricing power.

Are there any upcoming approvals or clinical trials for MOVANTIK?

Investigations into additional indications like IBS-C continue, with results expected over the next 2-3 years, potentially opening new markets.

How do regional pricing and reimbursement policies affect MOVANTIK?

Pricing varies significantly between the U.S. and EU, with reimbursement coverage influencing actual sales volumes. Regional health policies could either facilitate or hinder market expansion.

---

References

[1] IQVIA. (2023). Pharmaceutical Market Statistics.
[2] European Medicines Agency. (2018). MOVANTIK Summary of Product Characteristics.
[3] U.S. Food and Drug Administration. (2018). FDA Approval Document for MOVANTIK.
[4] MarketWatch. (2023). Pharmaceuticals Market Analysis.
[5] Pharmaceutical Research and Manufacturers of America. (2022). Industry Sales Data.